Please find attached Press Release dated 31st July 2026

Date: 31st July, 2026 To, To, BSE Limited National Stock Exchange of India Limited P. J. Towers, Dalal Street, Fort Exchange Plaza, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai-400 051 Ref.: BSE Scrip Code No. “533138” Ref.: “ASTEC” Debt Segment NSE: NCD-ASTEC-ISIN: INE563J08023 Sub.: Press Release The Board of Directors of Astec LifeSciences Limited (“the Company”), at its Meeting held on Friday, 31st July, 2026, has approved the Unaudited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter ended 30th June, 2026. We enclose a copy of the Press Release and the same is being placed on the website of the Company. Please take the above information on your records. Thanking you, Yours sincerely, For Astec LifeSciences Limited Tejashree Pradhan Company Secretary & Compliance Officer (FCS 7167) Encl.: As Above ASTEC LIFESCIENCES LIMITED “Godrej One”, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India CIN: L99999MH1994PLC076236 PRESS RELEASE Mumbai, 31st July 2026: Astec LifeSciences Limited (“Astec”) has today announced its financial results for the first quarter. FINANCIAL OVERVIEW Q1 FY27 Financial Summary • The Company reported consolidated total income of ₹84.3 crore in Q1FY27 as compared to ₹91.6 crore in Q1FY26. • The Company reported consolidated EBITDA of ₹0.1 crore in Q1FY27 as compared to EBITDA of ₹-10.5 crore in Q1FY26. • The Company reported a Loss after tax of ₹-18.7 crore in Q1FY27 as compared to a loss of ₹-33.0 crore in Q1FY26. HIGHLIGHTS OF CONSOLIDATED FINANCIAL PERFORMANCE (in ₹ crore) Particulars Q1FY27 Q1FY26 % Change Total Income 84.3 91.6 -8.0% Earnings before Depreciation, Interest and Tax 0.1 -10.5 NM (EBITDA) Profit/(Loss) before Tax (18.7) (33.0) NM Profit/(Loss) after Tax (18.7) (33.0) NM NM: Not Measurable CHAIRPERSON’S COMMENTS Commenting on the performance, Mr. Vishal Sharma, Chairperson, Astec LifeSciences Limited, said: The agrochemical sector is still dealing with the demand - supply imbalance since 2023 and this is expected to even out over the medium term which will structurally support the industry in a positive manner. Astec reported consolidated income of ₹84.3 crore in Q1 FY27 versus ₹91.6 crore in Q1 FY26. The Company achieved EBITDA breakeven in the quarter compared to an EBITDA loss of ₹10.5 crore in the same period last year, despite lower revenues. The improvement is supported by favourable product mix, improved margins in both the Enterprise and Contract Manufacturing segments and enhanced capacity utilization at its plants. Revenue from Enterprise Products grew 42% YoY to ₹51.8 crore in Q1 FY27, compared to ₹36.5 crore in Q1 FY26, primarily led by higher volumes and supported by improved realizations. Revenue from CDMO Products stood at ₹31.8 crore in Q1 FY27 compared to ₹54.6 crore in Q1 FY26. The year-on-year decline was largely attributable to a high base in the corresponding quarter. The company is taking steps to build its business development and growth capability along with new product introductions, while also exploring opportunities to drive efficiencies across its operations. (in ₹ crore) Revenue from Operations Q1FY27 Q1FY26 % Change (₹ crore) Category Breakdown Enterprise 51.8 36.5 41.6% Contract Manufacturing & New Products 31.8 54.6 (41.8%) Geography Breakdown Exports 33.3 45.9 (27.5 %) Domestic 50.3 45.2 11.3% - ENDS – About Astec LifeSciences Limited Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to over 18 countries including the United States and countries across Europe, West Asia, South-East Asia and Latin America and Africa. For more information on the Company, please log on to www.godrejastec.com For further information, please contact: S. Varadaraj Deepak Ochani Godrej Agrovet Limited Astec LifeSciences Limited Email: s.varadaraj@godrejagrovet.com Email:deepak.ochani@godrejastec.com Tel No.: +91 22 2519 4864 Tel No.: +91 22 2519 5777 Amit Pendse Godrej Agrovet Limited Email: amit.pendse@godrejagrovet.com Tel No.: +91 22 2519 4488 Disclaimer: “Some of the statements in this communication may be ‘forward looking statements’ within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company’s operations include changes in industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations.”